Press release
Non Small Cell Lung Cancer Pipeline Outlook Report 2025: MOA, Companies, Companies, Clinical Trials, Expanding Therapeutic Classes, and Future Market Impact Revealed
Curious about the latest updates in the NSCLC Pipeline? Click here to explore the therapies and trials making headlines @ NSCLC Pipeline Outlook Report [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the NSCLC Pipeline Report
* On 17 November 2025, AstraZeneca conducted a phase IIIb Study of Durvalumab as Consolidation Treatment for Patients Diagnosed With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Definitive Concurrent or Sequential Platinum-based Chemoradiation Therapy in Spain (ALBORAN).
* On 12 November 2025, BicycleTx Limited announced a study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with previously treated NECTIN4-amplified advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one line of therapy in the advanced/metastatic setting (see inclusion criteria below). The study will comprise of 2 cohorts: Cohort A (non-squamous NSCLC) and Cohort B (squamous NSCLC).
* DelveInsight's NSCLC Pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for NSCLC treatment.
* The leading NSCLC Companies such as Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology, Exelixis, ProfoundBio US Co., Beijing Pearl Biotechnology Limited Liability Company, Pfizer, OncoResponse, Inc., Next Point Therapeutics, Inc., Light Chain Bioscience - Novimmune SA, Medolution Ltd., Immunitas Therapeutics, Shanghai Henlius Biotech and others.
* Promising NSCLC Therapies such as Brigatinib, Tyrosine kinase inhibitor, AK104+anlotinib, Osimertinib, Gefitinib, SSGJ-707, JS111 capsules (AP-L1898), Atezolizumab, Tiragolumab, AK112, Pemetrexed, Paclitaxel and others.
Want to know which companies are leading innovation in NSCLC? Dive into the full pipeline insights @ NSCLC Clinical Trials Assessment [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The NSCLC Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The NSCLC Pipeline Report also highlights the unmet needs with respect to the NSCLC.
NSCLC Overview
Non-small cell lung cancer is the most common type of lung cancer. With this disease, cancer cells originate in your lung tissues. Non-small cell lung cancer grows slowly compared to small cell lung cancer but it often spreads to other parts of your body by the time it's diagnosed. So, early detection and non-small cell lung cancer treatment are essential.
NSCLC Emerging Drugs Profile
* V940: Merck Sharp & Dohme LLC
V940 is designed to stimulate an immune response by generating specific T cell responses based on the unique mutational signature of a patient's tumor. It is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine consisting of a single synthetic mRNA coding for up to 34 neoantigens that is designed and produced based on the unique mutational signature of the DNA sequence of the patient's tumor. Upon administration into the body, the algorithmically derived and RNA-encoded neoantigen sequences are endogenously translated and undergo natural cellular antigen processing and presentation, a key step in adaptive immunity. The drug is in Phase III stage for the treatment of NSCLC.
* QL1706: Qilu Pharmaceutical Co., Ltd.
QL1706 is an investigational bifunctional antibody with additional anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibody could increase the anti-tumor effect of anti-programmed cell death 1 (PD-1) antibody. QL1706 is a novel dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA4 IgG1 antibodies produced by a single cell line. The drug is in Phase III stage for the treatment of NSCLC.
* Zenocutuzumab (MCLA-128): Merus N.V.
Zenocutuzumab (MCLA-128; Zeno) is a Biclonics antibody that overcomes HER3 mediated NRG1 (or NRG1 fusion) signaling in tumor cells. Zeno docks on HER2, then binds to and blocks the NRG1 fusion-HER3 interaction and HER3 heterodimerization with HER2. It has a dual mechanism against cancer, as it prevents NRG1 fusions from binding to the protein HER3 and it blocks the interaction of HER3 with HER2, which the cancer cells depend on to survive and multiply. Currently, the drug is in Phase II stage for the treatment of NSCLC.
* ZW49: Zymeworks BC Inc.
ZW49 (zanidatamab zovodotin) is a bispecific anti-HER2 ADC that is based on the same antibody framework as ZW25 but armed with a cytotoxic payload. A biparatopic (targeting two different non-overlapping epitopes on ERBB2, on extracellular domains 2 (ECD2) and 4 (ECD4). ZW25 is an anti-HER2 biparatopic antibody which binds to the same domains as trastuzumab and pertuzumab. ZW25 simultaneously binds two distinct sites on HER2, a protein expressed on many types of cancer cells. This unique design results in multiple mechanisms of action, including dual HER2 signal blockade, increased antibody binding, receptor clustering, and removal of HER2 from the cell surface, and potent eector function. ZW49 is in Phase I of clinical trials for the treatment of non-small cell lung cancer.
If you're tracking ongoing NSCLC Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ NSCLC Treatment Drugs [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The NSCLC Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of NSCLC with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NSCLC Treatment.
* NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NSCLC market.
NSCLC Companies
Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology, Exelixis, ProfoundBio US Co., Beijing Pearl Biotechnology Limited Liability Company, Pfizer, OncoResponse, Inc., Next Point Therapeutics, Inc., Light Chain Bioscience - Novimmune SA, Medolution Ltd., Immunitas Therapeutics, Shanghai Henlius Biotech and others.
NSCLC pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
NSCLC Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
From emerging drug candidates to competitive intelligence, the NSCLC Pipeline Report covers it all - check it out now @ NSCLC Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the NSCLC Pipeline Report
* Coverage- Global
* NSCLC Companies- Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology, Exelixis, ProfoundBio US Co., Beijing Pearl Biotechnology Limited Liability Company, Pfizer, OncoResponse, Inc., Next Point Therapeutics, Inc., Light Chain Bioscience - Novimmune SA, Medolution Ltd., Immunitas Therapeutics, Shanghai Henlius Biotech and others.
* Promising NSCLC Therapies- Brigatinib, Tyrosine kinase inhibitor, AK104+anlotinib, Osimertinib, Gefitinib, SSGJ-707, JS111 capsules (AP-L1898), Atezolizumab, Tiragolumab, AK112, Pemetrexed, Paclitaxel and others.
* NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the NSCLC Treatment landscape in this detailed analysis @ NSCLC Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Non-Small-Cell Lung cancer (NSCLC): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Non-Small-Cell Lung cancer (NSCLC) - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* V940: Merck Sharp & Dohme LLC
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Zenocutuzumab (MCLA-128): Merus N.V.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ZW49: Zymeworks BC Inc.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Non-Small-Cell Lung cancer (NSCLC) Key Companies
* Non-Small-Cell Lung cancer (NSCLC) Key Products
* Non-Small-Cell Lung cancer (NSCLC) - Unmet Needs
* Non-Small-Cell Lung cancer (NSCLC) - Market Drivers and Barriers
* Non-Small-Cell Lung cancer (NSCLC) - Future Perspectives and Conclusion
* Non-Small-Cell Lung cancer (NSCLC) Analyst Views
* Non-Small-Cell Lung cancer (NSCLC) Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=non-small-cell-lung-cancer-pipeline-outlook-report-2025-moa-companies-companies-clinical-trials-expanding-therapeutic-classes-and-future-market-impact-revealed]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non Small Cell Lung Cancer Pipeline Outlook Report 2025: MOA, Companies, Companies, Clinical Trials, Expanding Therapeutic Classes, and Future Market Impact Revealed here
News-ID: 4280953 • Views: …
More Releases from ABNewswire
Golden Times Launches Space Series Playground, Raising the Bar for Safe and Inte …
Wenzhou Golden Times Amusement Toys CO., LTD. (Golden Times), a leading global manufacturer of playground and amusement equipment, has unveiled its latest innovation: the Space Series Playground. Designed for children aged 3 to 12, this new outdoor playground system combines cutting-edge interactive features, durable materials, and full EN 1177 certified impact-absorbing surfacing [https://www.goldentimestoy.com/knowledge/what-is-en-1177-and-why-is-it-critical-for-playground-surfacing-safety/], setting a new standard for safety and engagement in playgrounds worldwide.
The Space Series Playground is engineered to…
Cybersecurity Firm IBN Technologies Expands U.S. Security Capabilities Amid Rapi …
As cyber threats escalate, U.S. organizations face increasing pressure to secure digital operations. IBN Technologies, a leading cybersecurity firm, provides AI-driven monitoring, vulnerability assessments, SOC services, MDR, vCISO guidance, and compliance support. Their multi-layered solutions ensure continuous protection, operational efficiency, and regulatory alignment, helping companies maintain resilience and safeguard critical assets nationwide.
The U.S. cybersecurity market is at a critical inflection point as cyberattacks grow more sophisticated and frequent, prompting organizations…
Cybersecurity Firm IBN Technologies Strengthens U.S. Defense Against AI-Driven T …
IBN Technologies, a trusted cybersecurity firm, enhances U.S. organizations' defenses against advanced AI-driven threats. With 24/7 monitoring, vulnerability assessments, and compliance-focused services, IBN empowers businesses to secure cloud systems, manage regulatory demands, and reduce breach risk. Their integrated audits, SOC, MDR, and vCISO solutions ensure scalable, resilient, and forward-focused cybersecurity.
The U.S. cybersecurity landscape is entering a pivotal phase as cyberattacks become more advanced and persistent, pushing organizations to reinforce their…
Container Shipping Market to Reach USD 139.45 Billion by 2030, Fueled by Growing …
Mordor Intelligence has published a new report on the Container Shipping Market, offering a comprehensive analysis of trends, growth drivers, and future projections.
Container Shipping Market Outlook
According to Mordor Intelligence, the Container Shipping Market size [https://www.mordorintelligence.com/industry-reports/global-container-shipping-market?utm_source=abnewswire] is estimated at USD 119.65 billion in 2025, and is expected to reach USD 139.45 billion by 2030, at a CAGR of 3.11%. The Container Shipping Market share is being influenced by several key factors,…
More Releases for NSCLC
NSCLC Patient Insights You Can't Afford to Ignore! A DelveInsight Case Study - H …
DelveInsight, a global leader in healthcare market intelligence and consulting, has successfully partnered with a top-tier biopharmaceutical company specializing in oncology to provide an advanced epidemiology forecasting analysis of Non-Small Cell Lung Cancer (NSCLC). This comprehensive study focused on biomarker-specific segmentation to support strategic drug development, identify target patient populations, and optimize market access planning across global markets.
With the increasing complexity of NSCLC treatment, biomarker-driven therapies have emerged as a…
Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC
Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical…
NSCLC Market Global Industry Analysis and Forecast Till 2027
Any type of epithelial lung cancer that isn't small cell lung cancer is referred to as NSCLC (SCLC). Squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common kinds of NSCLC, although there are several more types that are less common, and all types can occur in atypical histologic variants.
Request Sample Copy of this Report: https://www.infinitybusinessinsights.com/request_sample.php?id=562904
Top Key Players Included in This Report: Merck KGa, Roche, Nlyte, Taxotere,…
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail…
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot:
NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit…
Global cancer immunotherapies Market 2016:Melanoma, Prostate cancer, NSCLC
Cancer Immunotherapies has brought an unprecedented change in the global cancer therapies market. Cancer immunotherapy can be defined as, the treatment that deploys the bodys immune system, by joining and boosting innate powers of the immune system to fight cancer.
Over the past few years, cancer immunotherapies have generated new waves of optimism in the global oncology market, unveiling huge untapped potential for the innovators. After years of jostling over how…
